Association of Glycemic Variability in Type 1 Diabetes With Progression of Microvascular Outcomes in the Diabetes Control and Complications Trial

John M Lachin, Ionut Bebu, Richard M Bergenstal, Rodica Pop-Busui, F John Service, Bernard Zinman, David M Nathan, DCCT/EDIC Research Group, John M Lachin, Ionut Bebu, Richard M Bergenstal, Rodica Pop-Busui, F John Service, Bernard Zinman, David M Nathan, DCCT/EDIC Research Group

Abstract

Objective: The Diabetes Control and Complications Trial (DCCT) demonstrated the beneficial effects of intensive versus conventional therapy on the development and progression of microvascular complications of type 1 diabetes. These beneficial effects were almost completely explained by the difference between groups in the levels of HbA1c, which in turn were associated with the risk of these complications. We assessed the association of glucose variability within and between quarterly 7-point glucose profiles with the development and progression of retinopathy, nephropathy, and cardiovascular autonomic neuropathy during the DCCT.

Research design and methods: Measures of variability included the within-day and updated mean (over time) of the SD, mean amplitude of glycemic excursions (MAGE), and M-value, and the longitudinal within-day, between-day, and total variances. Imputation methods filled in the 16.3% of expected glucose values that were missing.

Results: Cox proportional hazards models assessed the association of each measure of glycemic variation, as a time-dependent covariate, with the risk of retinopathy and nephropathy, and a longitudinal logistic regression model did likewise for cardiovascular autonomic neuropathy. Adjusted for mean blood glucose, no measure of within-day variability was associated with any outcome. Only the longitudinal mean M-value (over time) was significantly associated with microalbuminuria when adjusted for the longitudinal mean blood glucose and corrected for multiple tests using the Holm procedure.

Conclusions: Overall, within-day glycemic variability, as determined from quarterly glucose profiles, does not play an apparent role in the development of microvascular complications beyond the influence of the mean glucose.

Trial registration: ClinicalTrials.gov NCT00360893 NCT00360815.

© 2017 by the American Diabetes Association.

References

    1. The Diabetes Control and Complications Trial Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977–986
    1. The Diabetes Control and Complications Trial Research Group The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial. Diabetes 1995;44:968–983
    1. The Diabetes Control and Complications Trial Research Group The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial. Diabetes 1996;45:1289–1298
    1. Lachin JM, Genuth S, Nathan DM, Zinman B, Rutledge BN; DCCT/EDIC Research Group . Effect of glycemic exposure on the risk of microvascular complications in the Diabetes Control and Complications Trial--revisited. Diabetes 2008;57:995–1001
    1. Brownlee M, Hirsch IB. Glycemic variability: a hemoglobin A1c-independent risk factor for diabetic complications. JAMA 2006;295:1707–1708
    1. Monnier L, Mas E, Ginet C, et al. . Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 2006;295:1681–1687
    1. Service FJ, Molnar GD, Rosevear JW, Ackerman E, Gatewood LC, Taylor WF. Mean amplitude of glycemic excursions, a measure of diabetic instability. Diabetes 1970;19:644–655
    1. Kilpatrick ES, Rigby AS, Atkin SL. The effect of glucose variability on the risk of microvascular complications in type 1 diabetes. Diabetes Care 2006;29:1486–1490
    1. Bolli GB. Glucose variability and complications. Diabetes Care 2006;29:1707–1709
    1. Service FJ, O’Brien PC. The relation of glycaemia to the risk of development and progression of retinopathy in the Diabetic Control and Complications Trial. Diabetologia 2001;44:1215–1220
    1. Kilpatrick ES, Rigby AS, Atkin SL. Effect of glucose variability on the long-term risk of microvascular complications in type 1 diabetes. Diabetes Care 2009;32:1901–1903
    1. Siegelaar SE, Kilpatrick ES, Rigby AS, Atkin SL, Hoekstra JB, Devries JH. Glucose variability does not contribute to the development of peripheral and autonomic neuropathy in type 1 diabetes: data from the DCCT. Diabetologia 2009;52:2229–2232
    1. Kilpatrick ES, Rigby AS, Atkin SL. Mean blood glucose compared with HbA1c in the prediction of cardiovascular disease in patients with type 1 diabetes. Diabetologia 2008;51:365–371
    1. Kilpatrick ES, Rigby AS, Atkin SL. A1C variability and the risk of microvascular complications in type 1 diabetes: data from the Diabetes Control and Complications Trial. Diabetes Care 2008;31:2198–2202
    1. Kilpatrick ES, Rigby AS, Goode K, Atkin SL. Relating mean blood glucose and glucose variability to the risk of multiple episodes of hypoglycaemia in type 1 diabetes. Diabetologia 2007;50:2553–2561
    1. Nathan DM, McGee P, Steffes MW, Lachin JM; DCCT/EDIC Research Group . Relationship of glycated albumin to blood glucose and HbA1c values and to retinopathy, nephropathy, and cardiovascular outcomes in the DCCT/EDIC study. Diabetes 2014;63:282–290
    1. Early Treatment Diabetic Retinopathy Study Research Group Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Ophthalmology 1991;98(Suppl.):823–833
    1. DCCT Research Group The effect of intensive diabetes therapy on measures of autonomic nervous system function in the Diabetes Control and Complications Trial (DCCT). Diabetologia 1998;41:416–423
    1. Schlichtkrull J, Munck O, Jersild M. The M-value, an index of blood sugar control in diabetics. Acta Med Scand 1965;177:95–102
    1. Rubin DB. Multiple Imputation for Nonresponse in Surveys. New York, John Wiley & Sons, 1987
    1. van Buuren S. Flexible Imputation of Missing Data. Boca Raton, FL, Chapman & Hall/CRC, 2012
    1. White IR, Royston P, Wood AM. Multiple imputation using chained equations: issues and guidance for practice. Stat Med 2011;30:377–399
    1. Schafer JL, Yucel RM. Computational strategies for multivariate linear mixed-effects models with missing values. J Comput Graph Stat 2002;11:437–457
    1. Rubin DB, Schenker N. Multiple imputation for interval estimation from simple random samples with ignorable nonresponse. J Am Stat Assoc 1986;81:366–374
    1. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. New York, John Wiley & Sons, 1980
    1. Lachin JM. Biostatistical Methods: The Assessment of Relative Risks. 2nd ed. New York, John Wiley & Sons, 2011
    1. Nathan DM, Kuenen J, Borg R, Zheng H, Schoenfeld D, Heine RJ; A1c-Derived Average Glucose Study Group . Translating the A1C assay into estimated average glucose values. Diabetes Care 2008;31:1473–1478
    1. Holm S. A simple sequentially rejective multiple test procedure. Scand J Stat 1979;6:65–70
    1. Baghurst PA, Rodbard D, Cameron FJ. The minimum frequency of glucose measurements from which glycemic variation can be consistently assessed. J Diabetes Sci Technol 2010;4:1382–1385
    1. Giacco F, Du X, Carratú A, et al. . GLP-1 cleavage product reverses persistent ROS generation after transient hyperglycemia by disrupting an ROS-generating feedback loop. Diabetes 2015;64:3273–3284

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi